#ASCO19: Amgen shows off their latest BCMA BiTE update with plans to hustle ahead as rivals jostle for position
CHICAGO — Amgen’s R&D team is quite proud of their program for AMG 420, a BCMA-targeted bispecific T cell engager they plan to hustle through pivotal studies in search of an accelerated OK by the FDA. And the whole BiTE platform is being developed as an avenue to greatly expand their presence in the oncology market.
The pharma giant was on hand at ASCO to offer the latest update — a common theme at the meeting this year — on ‘420, while sharing the limelight with some of the rest of the BiTEs now working their way up the pipeline.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.